A shadow market for unapproved weight-loss medications is being driven by social media fitness personalities and sellers on communication apps, according to new investigations.
Experimental Drug Gaining Popularity Online
Retatrutide, which is still in research studies, is being advertised by online personalities for its supposed fat-burning effects. Viewers are urged to contact these accounts privately for supplier links, while also obtaining promotional offers.
Active Commerce on Messaging Platforms
Separately, a robust market exists on Telegram, where groups with numerous of participants share “before and after” photos, injection guides and claims of rapid UK delivery. Vendors promote the drug there before directing customers to other platforms for purchases.
Understanding Retatrutide
Retatrutide is an experimental injectable created by US drugmaker Eli Lilly. The treatment affects three gut hormones – glucagon-like peptide-1, GIP and glucagon. Preliminary studies suggest it could help individuals reduce up to a quarter of their total weight. Referred to as the “triple G”, the drug is being promoted online as the successor to Ozempic.
Medical Professionals Express Worries
Nevertheless, doctors and pharmacists have cautions that the distribution of what is still an unlicensed medication in the United Kingdom is worrisome and could result in users administering products of unknown origin.
Some experts stated the popularity for the experimental drug could be linked to the increasing price of licensed slimming products such as Mounjaro.
Legal Position and Enforcement
Marketing the unapproved drug on social media or messaging apps is prohibited in the UK, as it is an unapproved medication that must not be promoted or supplied for human use under the British medical regulations.
Several content creators attempt to circumvent the regulations by calling to the substance as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted drug, but promotion and supply can still breach medicines, marketing, and consumer regulations, potentially leading to fines, prosecution or prison.
Platform Response and Material Elimination
According to the social media company, the platform has removed problematic content and banned related keywords and query recommendations. The organization stated it was dedicated to keeping the service safe and investing in enhancing enforcement strategies.
Digital Trading Activities
Investigations also found communities with up to nine thousand participants marketing retatrutide using Telegram's built-in search feature, which operates like a online catalog. Entering “retatrutide” immediately displays channels with thousands of members, filled with photos of weight loss, positive testimonials and step-by-step instructions for preparing or administering at residence.
Within minutes of joining one community, a seller shared contact information, where the majority of transactions occur. The seller sent an instruction manual and promised shipping within 48 hours. When questioned whether the product was genuine, one vendor said: “You can’t be sure.” Another provided a photo of a alleged laboratory certificate. Not one inquired about weight, health issues or past usage.
Item Information and Costs
Inside these communities, messages display black plastic packages with Royal Mail labels, claiming to contain new batches. One communication read: “It took eight of us to load them this morning.”
Buyers can choose between powder vials, mixed at home with purified liquid, or pre-filled pens typically sold at £160 for 20mg. When questioned how long a pen should last, sellers give conflicting answers varying between a several days to “depends on your body”.
Platform Moderation and Security Actions
A spokesperson for Telegram stated it actively moderated harmful content on its platform including content that encouraged the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.
Healthcare Expert Warnings
“Individuals are administering materials they cannot confirm. Although the research behind this drug is sound, these online products may not contain what they advertise,” stated a pharmacy expert, the head of pharmaceutical services at a pharmacy service.
Dr Crystal Wyllie of Asda Online Doctor linked the surge in interest to recent cost increases for approved slimming medications such as Mounjaro. “With prices increasing, individuals are using social media. But counterfeit treatments are extremely risky. You can’t be certain what’s contained or whether the environment they were made in was clean,” she said.
Her staff has previously encountered individuals injured by personal administration from unconfirmed suppliers. “We understand the frustration, but buying from Telegram or WhatsApp is gambling with your health,” said Wyllie. “These materials could be impure or incorrectly dosed.”
Manufacturer Statement
A representative from Eli Lilly stated retatrutide was in third stage clinical trials and had not been reviewed or approved by any regulatory agency globally. “Consequently at this point no one can market [it] for human use,” they explained, adding that any product “falsely representing itself as a Lilly investigational substance not yet authorized … may subject users to potentially significant health risks”.
